Advertisement
U.S. markets closed

iShares Biotechnology ETF (IBB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
124.72+0.08 (+0.06%)
At close: 04:00PM EDT
124.77 +0.05 (+0.04%)
After hours: 06:18PM EDT
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • InvestorPlace

    3 Biotech ETFs Overdue for a Bounce

    Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon. Also, when the tides get rough, one needs the confidence and conviction to hang on (or buy on dips). Indeed, the turbulent seas of the higher-growth corners of the biotech

  • InvestorPlace

    Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits

    If you’re looking for biotech stocks to buy, the iShares Biotechnology ETF (NASDAQ:IBB) is an excellent place to start. It tracks the performance of the ICE Biotechnology Index, a collection of U.S. companies in the biotech industry. But that exchange traded fund (ETF) hasn’t done well in recent years. In the past three years, its total return was 0.95% in 2021, -13.69% in 2022 and 3.76% in 2023. Year-to-date (YTD), it’s up 2.91%, considerably less than the 8.74% for the SPDR S&P 500 ETF Trust (

  • InvestorPlace

    Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow’s Cures

    In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector’s most popular index, iShares Biotechnology ETF (NASDAQ:IBB), is dropping 9% year to date (YTD). Nevertheless, recent market developments point to a rebound on the horizon. It’s compelling investors to re-evaluate and hunt for the top biotech stocks offering robust upside potential ahead. Federal Reserve Chairman Jerome Powell’s hinting at potential rate cuts could spell a significant relief rally for biotech